Evaluation of pituitary tumor volume as a prognostic factor in acromegaly: A cross-sectional study in two centers

Table 1 Patients’ characteristics, n = 77

Variable
Female	35
Age at diagnosis, years (SD-IQR)	42 (12-46)
Time from diagnosis, years (SD-IQR)	9.9 (7.2-25)
Microadenoma, n (%)	26 (32)
Macroadenoma, n (%)	51 (66)
T2 weighted hyperintensity, n (%)	16 (20)
Adenoma volume, mm3 (SD-IQR)	4358 (6291-13602)
Vertical extension (supraselar or sphenoid sinus), n (%)	22 (29)
Horizontal extension (cavernous sinus), n (%)	20 (27)
IGF-1 at diagnosis, ng/mL (SD-IQR)	564.6 (334-859)
IGF-1 after surgery, ng/mL, (SD-IQR)	331 (198-478)
Treatment line 0 (No surgical therapy), n (%)	12 (15)
Treatment line 1, n (%)	16 (20)
Treatment line 2, n (%)	20 (25)
Treatment line 3, n (%)	16 (20)
Treatment line 4, n (%)	13 (16)
Controlled disease, n (%)	44 (57)
Uncontrolled disease, n (%)	33 (42)

IQR: Interquartile range: SD: Standard deviation.

Table 2 Magnetic resonance imaging predictors of disease control in acromegaly

N = 77	Controlled	Not controlled	P value
T2-weighted hyperintensity (n: 16), n (%)	8 (50)	8 (50)	0.57
Macroadenoma (n: 51), n (%)	28 (54)	23 (45)	0.88
Microadenoma (n: 26), n (%)	16 (60)	10 (40)
Adenoma volume	3202 (SD: 4845) (95%CI: 621-5784)	5513 (SD: 7447) (95%CI: 1545-9482)	0.15
Vertical extension (n: 22), n (%)	9 (40)	13 (59)	0.07
Horizontal extension (n: 20), n (%)	10 (50)	10 (50)	0.60

CI: Confidence interval; SD: Standard deviation.